Dovato's patents are set to expire in 2033 [1].
When can generic Dovato be expected?
Generic versions of Dovato are not anticipated to be available until 2033, when the key patents protecting the drug are set to expire [1]. This timeline is based on patent data available through DrugPatentWatch.com [1].
What is Dovato made of?
Dovato is a combination antiretroviral medication used to treat HIV infection [2]. It contains two active ingredients: dolutegravir and lamivudine [2]. Dolutegravir is an integrase strand transfer inhibitor (INSTI), and lamivudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) [2].
How does Dovato compare to other HIV treatments?
Dovato is a complete HIV treatment regimen in a single tablet taken once daily [3]. This two-drug combination offers an alternative to older, three-drug regimens for certain HIV patients, potentially reducing long-term drug exposure [3][4]. It is indicated for the treatment of HIV-1 infection in individuals 12 years of age and older and weighing at least 35 kg who have no known resistance to either dolutegravir or lamivudine [2].
What are the potential risks of taking Dovato?
Like all medications, Dovato can cause side effects. Common side effects include headache, diarrhea, nausea, insomnia, and fatigue [2]. More serious, though less common, side effects can include hypersensitivity reactions and liver problems [2]. Patients are advised to discuss any concerns with their healthcare provider.
Where can I find more information on Dovato patents?
Information regarding Dovato's patent expiration and other related intellectual property can be found on DrugPatentWatch.com [1].
*
**Sources
1. https://drugpatentwatch.com/p/dovato-patents
2. https://www.viread.com/hcp/dovato/
3. https://www.hiv.gov/hiv-basics/keeping-hiv-control/treatment/hiv-medications
4. https://www.medscape.com/viewarticle/dovato-single-tablet-hiv-regimen-201999487